Business

Rep. Barragán with President Biden & Vice President Harris for Lower Prescription Drug Price Announcement

 

LARGO, MD — Rep. Nanette Barragán (CA-44) joined President Joe Biden and Vice President Kamala Harris Aug 15 for their announcement of the first negotiated drug prices under Medicare through the Inflation Reduction Act, passed by Democrats and signed by President Biden two years ago.

In a historic first, the Inflation Reduction Act allows Medicare to negotiate prescription drug prices directly with drug companies for the first time, similar to the U.S. Department of Veterans Affairs and other federal agencies that already negotiate drug prices. The new prices for the first 10 drugs selected for negotiation will take effect in Medicare beginning in 2026.

“Two years ago, President Biden, Vice President Harris, and Democrats in Congress delivered on our promise to start lowering prescription drug costs for Americans,” said Rep. Barragán. “The Inflation Reduction Act ,for the first time, gave Medicare the power to reduce the skyrocketing price of prescription drugs that disproportionately impact low-income communities and communities of color. The negotiated drug prices announced today will help millions of Americans afford their medication for diabetes, cancer, heart failure and much more. In the first year alone, this will mean $1.5 billion in out-of-pocket savings for older Americans and people with disabilities who depend on these life saving medications, including over 800,000 Californians. I was proud to join President Biden and Vice President Harris in Maryland today to celebrate this historic accomplishment, made possible by Democrats in Congress. We will continue to fight to lower costs for American families everywhere.”

The new prices of the ten drugs announced today are:

Drug Commonly Treated Conditions List Price Negotiated Price
Eliquis

 

Prevention and treatment of blood clots $521 $231
Jardiance Diabetes, heart failure, chronic kidney disease $573 $197
Xarelto Prevention and treatment of blood clots, reduction of risk for patients with coronary or peripheral artery disease $517 $197
Januvia Diabetes $527 $113
Farxiga Diabetes, heart failure, chronic kidney disease $556 $178.50
Entresto Heart failure $628 $295
Enbrel Rheumatoid arthritis, psoriasis, psoriatic arthritis $7,106 $2,355
Imbruvica Blood cancers $14,934 $9,319
Stelara Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis $13,836 $4,695
Fiasp; NovoLog Diabetes $495 $119

 

 

Reporters Desk

Recent Posts

Public Health Alert: RAW FARM-Brand Cheddar Cheese Linked to Ongoing E. coli Outbreak

The Los Angeles County Department of Public Health is alerting the public to an ongoing…

9 hours ago

LBCC Faculty Assn. Opens Endorsement Process for 2026 College Board Candidates

  LONG BEACH – The Long Beach City College Faculty Association or LBCCFA is welcoming…

11 hours ago

L.A. County Targets Copper Theft as Major Global Events Approach

Since 2020, in the city of Los Angeles alone—just one of 88 cities within Los…

12 hours ago

Extreme Heat Hits L.A.; City Activates Resources to Keep Residents Safe

  LOS ANGELES – With an Extreme Heat Warning now in effect through March 20,…

13 hours ago

When Centering and Silencing Women No Longer Work

Celebrating women can be a superficial balm to calm people’s nerves in highly stressful times,…

1 day ago

Draft Environmental Review Issued for Berths 121–131 Terminal Project

  LOS ANGELES – As the result of a multiyear environmental review process, the Los…

2 days ago